Sign In
Buy AGIO
$30.02
-2.73 (-8.34%)
At Close: Jul 31, 2026
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026)
05:36am, Friday, 24'th Apr 2026
A rival company's trial results had a negative impact on Agios' stock this week.
Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to Decline
11:01am, Wednesday, 22'nd Apr 2026
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Stock Sinks 23% as NVO's PKR Activator Meets Goal in SCD Study
10:36am, Tuesday, 21'st Apr 2026
AGIO shares plunge after Novo Nordisk's strong sickle cell data raised doubts about mitapivat's competitiveness and approval prospects.
Here's Why Agios Pharmaceuticals Crashed 23% Today
12:19pm, Monday, 20'th Apr 2026
The market is concerned about the diminished market potential for Agios' mitapavit following today's newsflow.
SG Americas Securities LLC Increases Position in Agios Pharmaceuticals, Inc. $AGIO
05:18am, Wednesday, 08'th Apr 2026
SG Americas Securities LLC raised its position in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) by 68.0% during the fourth quarter, according to the company in its most recent disclosure with the Securit
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
07:00am, Monday, 06'th Apr 2026
CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wi
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
12:16pm, Wednesday, 01'st Apr 2026
Agios Pharmaceuticals jumps 14% as it moves toward accelerated FDA approval for mitapivat in sickle cell disease after key regulatory feedback.
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
09:00am, Wednesday, 01'st Apr 2026
NEW YORK, April 1, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO) concern
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
06:50am, Wednesday, 01'st Apr 2026
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mo
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today
12:08pm, Tuesday, 31'st Mar 2026
Agios Pharmaceuticals' mitapivat has shown tremendous promise as a treatment for sickle cell disease. It's been so promising, in fact, that the U.S. Food and Drug Administration is allowing the compan
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything
12:03pm, Tuesday, 31'st Mar 2026
2,959 shares sold for a total of ~$82,000 at a weighted average price of around $27.80 per share on March 5, 2026. The transaction represented 36.5% of Krishnan's direct common stock holdings, reducin
AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money
09:00am, Tuesday, 31'st Mar 2026
NEW YORK, March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agios Pharmaceuticals, Inc.: Due to the forgoing, The Gross Law Firm is investigating potenti
PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake
08:45am, Tuesday, 31'st Mar 2026
With physicians identifying up to one-third of patients as candidates, early adoption reflects strong enthusiasm tempered by cautious real-world uptake. With physicians identifying up to one-third of
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
07:00am, Tuesday, 31'st Mar 2026
Company has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway Company plans to submit mitapivat sNDA in sickle cell disease in the coming m
Agios Pharmaceuticals, Inc. $AGIO Stock Holdings Increased by Assenagon Asset Management S.A.
03:32am, Tuesday, 31'st Mar 2026
Assenagon Asset Management S.A. boosted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) by 64.5% in the undefined quarter, according to the company in its most recent disclosure w
